NDA 210884 · Tonix Meds
Tosymra
Sumatriptan · Nasal · Serotonin-1b and Serotonin-1d Receptor Agonist
Last checked: Nov 20, 2026Latest source record: Jan 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jan 25, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
113
33 Phase 3, 5 recruiting
FAERS reports
18,395
11,313 serious, 585 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established ( 1 ) Not indicated for the preventive treatment of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with TOSYMRA, reconsider the diagnosis before TOSYMRA is administered to treat any subsequent attacks. TOSYMRA is not indicated for the preventive treatment of migraine. TOSYMRA is not indicated for the treatment of cluster headache.
Mechanism: Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TOSYMRA · SUMATRIPTAN 10MG/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00433732 · 1,400 participants · Start Aug 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Little Rock, Arkansas; Chapel Hill, North Carolina
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00898677 · 1,268 participants · Start Sep 1995 · Primary completion May 1996
Drug: rizatriptan benzoate; rizatriptan benzoate and 2 more · For: Migraine Headache
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00434083 · 1,200 participants · Start Jul 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Chapel Hill, North Carolina; Nashville, Tennessee
- Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and PlaceboPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986270 · 1,141 participants · Start Dec 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01430442 · 1,026 participants · Start Oct 2011 · Primary completion May 2012
Drug: Rimegepant; Placebo and 1 more · For: Migraine; Acute Treatment of Migraine
Sites: Scottsdale, Arizona; Tempe, Arizona; San Francisco, California · 41 sites in all
- Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack StudyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986088 · 1,008 participants · Start Nov 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897104 · 933 participants · Start Aug 1995 · Primary completion May 1996
Drug: rizatriptan benzoate (MK0462); Comparator: sumatriptan and 1 more · For: Migraine Headache
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,839
- headache1,501
- migraine1,273
- nausea1,260
- fatigue1,073
- dizziness887
- pain851
- off label use838
- vomiting720
- dyspnoea658
- diarrhoea648
- anxiety613
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 12 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 20 |
| 2009 | 46 |
| 2010 | 83 |
| 2011 | 100 |
| 2012 | 334 |
| 2013 | 371 |
| 2014 | 554 |
| 2015 | 790 |
| 2016 | 1,137 |
| 2017 | 1,168 |
| 2018 | 1,728 |
| 2019 | 1,878 |
| 2020 | 1,637 |
| 2021 | 1,524 |
| 2022 | 1,432 |
| 2023 | 1,642 |
| 2024 | 1,340 |
| 2025 | 1,445 |
| 2026 | 1,132 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tosymra (Sumatriptan)
2024 spending
$382K
Beneficiaries
173
473 claims
Per beneficiary
$2,208
$107.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $22,593 |
| 2022 | $428,134 |
| 2023 | $492,449 |
| 2024 | $381,934 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- Sumatriptan.
Kaube H, May A, Pfaffenrath V · BMJ 1994 · Clinical Trial, Comment
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, et al. · JAMA Netw Open 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
Maghbooli M, Golipour F, Moghimi Esfandabadi A, et al. · Phytother Res 2014 · Comparative Study, Randomized Controlled Trial
Sponsor: Tonix Meds
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.